Each quarter the Nanotechnology Characterization Laboratory (NCL) accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program. In June, a collaborative immunotherapy project between iMed.ULisboa and Tel Aviv University was selected to be part of the NCL international program established by the National Cancer Institute, in the USA.

This project coordinated by iMed.ULisboa researcher Helena Florindo (BioNanoSciences – Drug Delivery & Immunoengineering Lab) and Tel Aviv University researcher Ronit Stachi-Fainaro focuses on the implementation of a novel precision immuno-oncology therapy – TanoMed – aiming to improve therapeutic efficacy of immunotherapies for cancer treatment.

The collaboration with the NCL team will involve re-assessing the technology in-depth and validating its feasibility for clinical translation and commercialization. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics.

More information here.